$SHOT: Safety Shot to Develop Detox Product for Alcohol

New Post Public Reply Private Reply Replies (1) Message Board
Lee Adams
259
$SHOT: Safety Shot to Develop Detox Product for Alcohol Poising, Plans to File IND with U.S. FDA

Concentrated form of Safety Shot may be effective as a rapid treatment for alcohol poising which causes 2,200 deaths each year from an estimated 20,000 cases annually in the U.S.

Acute alcohol consumption leads to 52 million hospital emergency department visits annually


JUPITER, FL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced it intends to develop its Safety Shot functional beverage platform in a unique concentrated form to treat alcohol poisoning in hospital and emergency settings. The Safety Shot beverage, set to launch Q4 2023, is the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity.

The Safety Shot platform works through four different Mechanisms of Action including improving central nervous system (CNS) activity, cognition, and motor cortex function. It is designed to rapidly break down blood alcohol levels and prevent residual alcohol in the body from being absorbed through the gut by creating a protective shield around the gut wall.

Over 52 million people in the U.S. were admitted to hospital emergency departments due to acute alcohol consumption in 2020. There are an estimated 20,000 cases of alcohol poisoning each year in the U.S. Severe complications from alcohol poisoning can include choking, asphyxiation, dehydration, seizures, hypothermia, cardiac arrest, brain damage, and death. According to the U.S. Centers for Disease Control, 2,200 people die of alcohol poisoning each year in the U.S., or about 6 people each day.

Through its Jupiter Wellness business segment which develops over-the-counter and prescription-grade health and wellness products, Safety Shot has a well-established clinical development infrastructure and expertise.

"We believe a concentrated form of Safety Shot could offer an easy-to-administer, immediately supportive aid or treatment for acute alcohol consumption to help prevent alcohol poisoning and related deaths. With 52 million people rushed to the ER each year due to acute alcohol consumption, we believe that prescription-grade Safety Shot could be used in a variety of settings including ambulances, hospitals, clinics, and entertainment venue-based medical emergency centers," stated Dr. Glynn Wilson, Safety Shot's Chief Scientific Officer. "We anticipate filing an investigational new drug (IND) application with the U.S. Food and Drugs Administration (FDA) for this alcohol poisoning related indication."

About Safety Shot

Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. The Company plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://jupiterwellness.com/email-alerts/ and by following Jupiter Wellness on Twitter and LinkedIn.

Forward Looking Statements

This communication contains forward-looking statements regarding Jupiter Wellness, including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company's current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness' control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Jupiter Wellness and, including those described from time to time under the caption "Risk Factors" and elsewhere in Jupiter Wellness' Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness' Annual Report on Form 10-K for the year ended December 31, 2023 and future filings and reports by Jupiter Wellness. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Safety Shot Media Contact:

Phone: 561-244-7100

Email: info@JupiterWellness.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Kinetic Seas Incorporated Secures First Customer Success

Updated Category News Views 56

Kinetic Seas Incorporated Secures First Customer and Financial Growth Kinetic Seas Incorporated (OTC: ECGR) is excited to announce the signing of its first customer, along with impressive revenue results for the second quarter. This milestone marks a significant step forward as the company pursues its goals in the artificial intelligence sector. Second Quarter Revenue...

Continue Reading
Webinar Guide for Veterans to Maximize Benefits Offered by CCK Law

Updated Category News Views 134

Helping Veterans Discover VA Benefits with a Free Webinar Chisholm Chisholm & Kilpatrick LTD (CCK Law), a preeminent veterans disability law firm, is excited to introduce a free, on-demand webinar aimed at assisting veterans in uncovering valuable VA benefits that many may be unaware of. Insights from the Experts The webinar, dubbed "Biggest Benefits Veterans Overlook,"...

Continue Reading
Tech Market Shifts: Navigating Opportunities and Challenges Ahead

Updated Category News Views 161

Understanding Recent Market Dynamics In recent weeks, global markets have been experiencing heightened volatility, particularly in the technology sector. With various significant events unfolding—including new political leadership in Japan and shifts in economic data—investors are carefully analyzing these developments to navigate potential risks and opportunities....

Continue Reading
Michael Beland Joins Advance Auto Parts as Chief Accounting Officer

Updated Category News Views 720

Welcome Michael Beland to Advance Auto Parts Advance Auto Parts, Inc. (NYSE: AAP), known for its significant role in the automotive aftermarket, recently made an important announcement regarding its executive leadership. The company has appointed Michael Beland as the new senior vice president, controller, and chief accounting officer, marking a pivotal addition to their...

Continue Reading
Recall Movement Against Governor Newsom Gains Momentum

Updated Category News Views 276

Recall Movement Gains Traction in California In an unprecedented move, SavingCalifornia.vote has taken a significant step to initiate a recall against Governor Gavin Newsom. This initiative marks a pivotal moment in California's political landscape. The organization is gathering support and will soon submit the official notice of intent to recall, alongside the necessary...

Continue Reading